panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 130
- Registration Number
- NCT06714357
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 500
- Registration Number
- NCT06509126
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 450
- Registration Number
- NCT06252649
- Locations
- 🇺🇸
Orchard Healthcare Research Inc, Skokie, Illinois, United States
🇺🇸Pikeville Medical Center, Pikeville, Kentucky, United States
🇺🇸Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 73
- Registration Number
- NCT06245356
- Locations
- 🇫🇷
Institut du Cancer d'Avignon, Avignon, France
🇫🇷CHU Jean Minjoz, Besançon, France
🇫🇷Centre Hospitalier de Cholet, Cholet, France
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT06194877
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
- Conditions
- Interventions
- Biological: PanitumumabOther: Indium In 111 PanitumumabProcedure: Single Photon Emission Computed TomographyProcedure: Computed TomographyProcedure: Surgical ProcedureOther: Imaging agentProcedure: Intraoperative ImagingProcedure: Near Infrared ImagingProcedure: ElectrocardiographyProcedure: Biospecimen Collection
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05901545
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 408
- Registration Number
- NCT05863195
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.